Active Wall St. announces its post-earnings coverage on AngioDynamics Inc. (NASDAQ: ANGO). The company posted its fiscal 2017 first quarter results on October 05th, 2016. The provider of minimally invasive medical devices used for vascular access, surgery, peripheral vascular disease, and oncology topped market expectations and also reaffirmed its FY17 outlook. Register with us now for your free membership at: http://www.activewallst.com/register/.
Today, AWS is promoting its earnings coverage on ANGO. Get our free coverage by signing up to: http://www.activewallst.com/registration-3/?symbol=ANGO.
For the three months ended on August 31st, 2016, AngioDynamics reported sales of $88.1 million; an increase of 5% compared with $83.8 million a year ago and topped analysts’ estimates of $86 million.
For Q1 FY17, the Company recorded net income of $1.3 million, or $0.04 on a per share basis, driven by volume growth and continued margin improvement compared to a net loss of $0.8 million, or $0.02 on a per share basis, in Q1 FY16. On an adjusted basis, AngioDynamics reported net income of $6.4 million, or $0.17 per share, up by 54.5% compared to an adjusted net income of $4.0 million, or $0.11 per share, in Q1 FY16, beating Wall Street’s expectations of earnings of $0.13 per share. The rise in earnings was attributed to growth in the Peripheral Vascular franchise leveraging opportunities created by the Cook Medical recall in May 2016.
During Q1 FY17, AngioDynamics reported that Peripheral Vascular net sales were $51.4 million up 9% compared to $47.1 million in Q1 FY16, driven primarily by growth in its core business. The company generated Vascular Access net sales of $25.0 million in the reported quarter, increased by 1% compared to $24.6 million a year ago. Oncology/Surgery net sales in Q1 FY17 were $11.1 million, down 2% compared to $11.3 million in Q1 FY16, primarily driven by lower RF sales. On a geographical basis, US net sales in Q1 FY17 were $71.8 million compared to $68.4 million in the year ago first quarter. Overall International net sales in the reported quarter were $15.7 million compared to $14.7 million a year ago.
Gross margin for Q1 FY17 was 51.1%, up 30 basis points compared to Q4 FY16, primarily driven by the company’s ability to leverage increased volume due to the Cook Medical recall. Gross margins were 70 basis points lower than Q1 FY16 on pricing pressure and the mix of products sold. Adjusted EBITDA in Q1 FY17 was $14.9 million, or $0.40 per share, compared to $11.6 million, or $0.32 per share, in Q1 FY16.
During Q1 FY17, AngioDynamics generated $7.4 million in operating cash flow and $7.0 million in free cash flow. As of August 31, 2016, the company’s cash and cash equivalents were $37.4 million versus $32.2 million at the end of the year-ago period Long-term debt was $100.7 million as of August 31, 2016, compared to $104.3 million as of May 31, 2016. Cash flow from operations was $7.4 million in the reported quarter versus $4.7 million a year ago.
The Company announced its FY17 guidance will remain unchanged, with net sales guidance of $355 million to $360 million and adjusted earnings in the range of $0.62 per share to $0.65 per share. The Company reiterated its FY17 free cash flow guidance of greater than $30 million.
At the closing bell, on Thursday, October 06, 2016, AngioDynamics’ stock climbed slightly by 0.33%, ending the trading session at $16.53. A total volume of 544.71 thousand shares were traded at the end of the day, which was higher than the 3-month average volume of 259.40 thousand shares. In the last one month and previous three months, shares of the company have advanced 13.97% and 50.23%, respectively. Moreover, the stock gained 36.12% since the start of the year.
Active Wall Street:
Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
AWS has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.